Having shown that R848-BPDs display promising capability to control tumor growth and improve survival in murine tumor models, we next sought to examine whether their mechanism of action is due to immune stimulation via TLR activation because R848 canonically activates TLR7/8 expressed by myeloid cells. This evidence concerns the gene TLR7 and neoplasm.